IP Library › Granted Patent US 12,195,805
Granted Patent B2
US 12,195,805 · App. 16/969,304 · Granted Jan 14, 2025

Methods for subtyping of bladder cancer

Inventors: Hawazin Faruki (Durham, NC); Greg Mayhew (Durham, NC); Myla Lai-Goldman (Durham, NC); Charles Perou (Carrboro, NC)
Assignees: GeneCentric Therapeutics, Inc.; University of North Carolina at Chapel Hill
C12Q1/6886C12Q1/6869C12Q2600/158
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,195,805
App. No.
16/969,304
Granted
Jan 14, 2025
Kind
B2
Abstract

Methods and compositions are provided for determining a subtype of Muscle Invasive Bladder Cancer (MIBC) in an individual by detecting the expression level of at least one classifier biomarker selected from a group of gene signatures for MIBC. Also provided herein are methods and compositions for determining the response of an individual with a MIBC subtype to a therapy such as immunotherapy.

Claims (13)

1. A method of assaying a bladder sample obtained from a human patient, the method comprising measuring a nucleic acid expression level of each and every classifier biomarker from a set of classifier biomarkers consisting of only aldehyde dehydrogenase 1 family member L2 (ALDH1L2), annexin A6 (ANXA6), arylsulfatase family member I (ARSI), breast carcinoma amplified sequence 1 (BCAS1), basonuclin 1 (BNC1), chromosome 10 open reading frame 99 (C10orf99), HID1 domain containing (C17orf28), calpain 5 (CAPN5), coiled-coil domain containing 80 (CCDC80), collagen type VI alpha 2 chain (COL6A2) carboxypeptidase X, M14 family member 2 (CPXM2), collagen triple helix repeat containing 1 (CTHRC1), desmoglein 3 (DSG3), elastin microfibril interfacer 1 (EMILIN1), epsin 3 (EPN3), envoplakin (EVPL), fibroblast activation protein alpha (FAP), fibrillin 1 (FBN1), fibroblast growth factor 7 (FGF7), flavin containing monooxygenase 9 pseudogene (FMO9P), fibronectin type III domain containing 1 (FNDC1), gamma-aminobutyric acid type B receptor subunit 2 (GABBR2), glutamine-fructose-6-phosphate transaminase 2 (GFPT2) gamma-glutamyltransferase 6 (GGT6), gremlin 1, DAN family BMP antagonist (GREM1), grainyhead like transcription factor 3 (GRHL3), interleukin 20 receptor subunit beta (IL20RB), keratin 6A (KRT6A), keratin 6B (KRT6B), keratin 6C (KRT6C), leiomodin 1 (LMOD1), HECTD2 antisense RNA 1 (LOC100188947), murine retrovirus integration site 1 homolog (MRVI1), neuropilin 2 (NRP2), PDZ and LIM domain 3 (PDLIM3), phospholipase A2 group IVF (PLA2G4F), podocan (PODN), periostin (POSTN), paired related homeobox 1 (PRRX1), adhesion molecule 4 (PVRL4), Rap guanine nucleotide exchange factor like 1 (RAPGEFL1), ras homolog family member U (RHOU), ras homolog family member V (RHOV), signal peptide, CUB domain and EGF like domain containing 2 (SCUBE2), syndecan 1 (SDC1), serpin family B member 13 (SERPINB13) secreted frizzled related protein 2 (SFRP2), secreted frizzled related protein 4 (SFRP4), solute carrier family 30 member 2 (SLC30A2), SPARC related modular calcium binding 2 (SMOC2), sorting nexin 31 (SNX31), small proline rich protein 2A (SPRR2A), scavenger receptor cysteine rich family member with 5 domains (SSC5D), T-box 3 (TBX3), transducin like enhancer of split 2 (TLE2), TOX high mobility group box family member 3 (TOX3), uroplakin 1A (UPK1A), uroplakin 2 (UPK2), uroplakin 3A (UPK3A) and zinc finger protein 750 (ZNF750), wherein the measuring is performed by an amplification, hybridization and/or sequencing assay.

2. The method of claim 1 , wherein the bladder sample was previously diagnosed as being muscle invasive bladder cancer (MIBC).

3. The method of claim 1 , wherein the amplification, hybridization and/or sequencing assay is selected from the group consisting of quantitative real time reverse transcriptase polymerase chain reaction (qRT-PCR), RNAseq, microarray analysis, gene chip analysis, Serial Analysis of Gene Expression (SAGE), Rapid Analysis of Gene Expression (RAGE), nuclease protection assays, and Northern blotting.

4. The method of claim 1 , wherein the bladder sample is a formalin-fixed, paraffin-embedded (FFPE) bladder tissue sample, fresh or a frozen bladder tissue sample, an exosome, wash fluids, cell pellets, or a bodily fluid obtained from the bladder of the human patient.

5. A method of treating muscle invasive bladder cancer (MIBC) in a human subject, the method comprising: measuring in a bladder sample obtained from the human subject, a nucleic acid expression level of each and every classifier biomarker in a set of classifier biomarkers consisting of only ALDH1L2, ANXA6, ARSI, BCAS1, BNC1, C10orf99, C17orf28, CAPN5, CCDC80, COL6A2, CPXM2, CTHRC1, DSG3, EMILIN1, EPN3, EVPL, FAP, FBN1, FGF7, FMO9P, FNDC1, GABBR2, GFPT2, GGT6, GREM1, GRHL3, IL20RB, KRT6A, KRT6B, KRT6C, LMOD1, LOC100188947, MRVI1, NRP2, PDLIM3, PLA2G4E, PODN, POSTN, PRRX1, PVRL4, RAPGEFL1, RHOU, RHOV, SCUBE2, SDC1, SERPINB13, SFRP2, SFRP4, SLC30A2, SMOC2, SNX31, SPRR2A, SSC5D, TBX3, TLE2, TOX3, UPK1A, UPK2, UPK3A and ZNF750, and wherein the nucleic acid expression level of each and every classifier biomarker from the set of classifier biomarkers indicates a subtype of MIBC selected from the group consisting of luminal, luminal infiltrated, basal, and basal infiltrated/neuronal; and administering a therapeutic agent based on the subtype of MIBC, wherein if the subtype of MIBC is luminal then the therapeutic agent is an FGFR3 inhibitor, if the subtype of MIBC is luminal-infiltrated then the therapeutic agent is an immunotherapy, if the subtype is basal then the therapeutic is chemotherapy or immunotherapy and if the subtype of MIBC is basal infiltrated/neuronal then the therapeutic is chemotherapy.

6. The method of claim 5 , further comprising a separate measuring step that comprises measuring the nucleic acid expression level of at least one biomarker from an additional set of biomarkers, wherein the additional set of biomarkers consists of only BIRC5, CCNB1, CDC20, CDCA1, CEP55, KNTC2, MKI67, PTTG1, RRM2, TYMS, UBE2C, TP53, RB1, FGFR2, FGFR3, and ERBB2.

7. The method of claim 5 , wherein the measuring the expression level is conducted using an amplification, hybridization and/or sequencing assay, wherein the amplification, hybridization and/or sequencing assay is selected from the group consisting of performing quantitative real time reverse transcriptase polymerase chain reaction (qRT-PCR), RNAseq, microarray analysis, gene chip analysis, Serial Analysis of Gene Expression (SAGE), Rapid Analysis of Gene Expression (RAGE), nuclease protection assays and Northern blotting.

8. The method of claim 5 , wherein the bladder sample is a formalin-fixed, paraffin-embedded (FFPE) bladder tissue sample, fresh or a frozen tissue sample, an exosome, wash fluids, cell pellets, or a bodily fluid obtained from the bladder of the human patient.

9. The method of claim 1 , further comprising measuring a nucleic acid expression level of each and every classifier biomarker from the set of classifier biomarkers consisting of only ALDH1L2, ANXA6, ARSI, BCAS1, BNC1, C10orf99, C17orf28, CAPN5, CCDC80, COL6A2, CPXM2, CTHRC1, DSG3, EMILIN1, EPN3, EVPL, FAP, FBN1, FGF7, FMO9P, FNDC1, GABBR2, GFPT2, GGT6, GREM1, GRHL3, IL20RB, KRT6A, KRT6B, KRT6C, LMOD1, LOC100188947, MRVI1, NRP2, PDLIM3, PLA2G4F, PODN, POSTN, PRRX1, PVRL4, RAPGEFL1, RHOU, RHOV, SCUBE2, SDC1, SERPINB13, SFRP2 SFRP4, SLC30A2, SMOC2, SNX31, SPRR2A, SSC5D, TBX3, TLE2, TOX3, UPK1A, UPK2, UPK3A and ZNF750 in a control luminal sample, luminal infiltrated sample, basal sample or basal infiltrated/neuronal sample.

10. The method of claim 5 , where further comprising comparing the measured nucleic acid expression levels of each and every classifier biomarker from the set of classifier biomarkers consisting of only ALDH1L2, ANXA6, ARSI, BCAS1, BNC1, C10orf99, C17orf28, CAPN5, CCDC80, COL6A2, CPXM2, CTHRC1, DSG3, EMILIN1, EPN3, EVPL, FAP, FBN1, FGF7, FMO9P, FNDC1, GABBR2, GFPT2, GGT6, GREM1, GRHL3, IL20RB, KRT6A, KRT6B, KRT6C, LMOD1, LOC100188947, MRVI1, NRP2, PDLIM3, PLA2G4F, PODN, POSTN, PRRX1, PVRL4, RAPGEFL1, RHOU, RHOV, SCUBE2, SDC1, SERPINB13, SFRP2, SFRP4, SLC30A2, SMOC2, SNX31, SPRR2A, SSC5D, TBX3, TLE2, TOX3, UPK1A, UPK2, UPK3A and ZNF750 in the bladder sample obtained from the human subject to the nucleic acid expression levels of each and every classifier biomarker from the set of classifier biomarkers consisting of only ALDH1L2, ANXA6, ARSI, BCAS1, BNC1, C10orf99, C17orf28, CAPN5, CCDC80, COL6A2, CPXM2, CTHRC1, DSG3, EMILIN1, EPN3, EVPL, FAP, FBN1, FGF7, FMO9P, FNDC1, GABBR2, GFPT2, GGT6, GREM1, GRHL3, IL20RB, KRT6A, KRT6B, KRT6C, LMOD1, LOC100188947, MRVI1, NRP2, PDLIM3, PLA2G4F, PODN, POSTN, PRRX1, PVRL4, RAPGEFL1, RHOU, RHOV, SCUBE2, SDC1, SERPINB13, SFRP2, SFRP4, S LC30A2, SMOC2, SNX31, SPRR2A, SSC5D, TBX3, TLE2, TOX3, UPK1A, UPK2, UPK3A and ZNF750 in at least one sample training set(s), wherein the at least one sample training set is a reference MIBC luminal sample, a reference MIBC luminal infiltrated sample, a reference MIBC basal sample, a reference MIBC basal infiltrated/neuronal sample or a combination thereof; and classifying the subtype of MIBC as luminal, luminal infiltrated, basal or basal infiltrated/neuronal based on the results of the comparing step.

11. The method of claim 10 , wherein the comparing step comprises applying a statistical algorithm which comprises determining a correlation between the nucleic acid expression levels of each classifier biomarker from the plurality of classifier biomarkers obtained from the lung sample and the nucleic acid expression levels of each classifier biomarker from the plurality of classifier biomarkers from the at least one training set(s); and classifying the subtype of MIBC as luminal, luminal infiltrated, basal or basal infiltrated/neuronal subtype based on the results of the statistical algorithm.

12. The method of claim 5 , wherein the chemotherapy is cisplatin-based neoadjuvant therapy if the subtype of MIBC is basal or etoposide-cisplatin therapy if the subtype of MIBC is basal-infiltrated/neuronal.

13. The method of claim 5 , wherein the immunotherapy is an immune checkpoint inhibitor if the subtype of MIBC is luminal-infiltrated.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 8, 2022
From: PEROU, CHARLES M.
To: THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
Reel/Frame 058927/0784 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 8, 2022
From: LAI-GOLDMAN, MYLA; FARUKI, HAWAZIN; MAYHEW, GREG
To: GENECENTRIC THERAPEUTICS, INC.
Reel/Frame 058927/0812 →
Continuity (2)
Provisional Application 62629975 · Feb 13, 2018
Related Publication 20210054464A1 · Feb 25, 2021
References Cited (80)
US 4483155A · Stiles · 1984 [cited by applicant]
US 4683202A · Mullis · 1987 [cited by applicant]
US 5384261A · Winkler et al. · 1995 [cited by applicant]
US 5445934A · Fodor et al. · 1995 [cited by applicant]
US 5677195A · Winkler et al. · 1997 [cited by applicant]
US 5708153A · Dower et al. · 1998 [cited by applicant]
US 5744305A · Fodor et al. · 1998 [cited by applicant]
US 5770358A · Dower et al. · 1998 [cited by applicant]
US 5770722A · Lockhart et al. · 1998 [cited by applicant]
US 5789162A · Dower et al. · 1998 [cited by applicant]
US 5800992A · Fodor et al. · 1998 [cited by applicant]
US 5854033A · Lizardi · 1998 [cited by applicant]
US 5856174A · Lipshutz et al. · 1999 [cited by applicant]
US 5874219A · Rava et al. · 1999 [cited by applicant]
US 5922591A · Anderson et al. · 1999 [cited by applicant]
US 6020135A · Levine et al. · 2000 [cited by applicant]
US 6033860A · Lockhart et al. · 2000 [cited by applicant]
US 6040138A · Lockhart et al. · 2000 [cited by applicant]
US 6040193A · Winkler et al. · 2000 [cited by applicant]
US 6344316B1 · Lockhart et al. · 2002 [cited by applicant]
US 7473767B2 · Dimitrov · 2009 [cited by applicant]
US 8492094B2 · Dimitrov et al. · 2013 [cited by applicant]
US 20110143959A1 · Nativ et al. · 2011 [cited by applicant]
US 20140295416A1 · Zarbl et al. · 2014 [cited by applicant]
US 20150292030A1 · McConkey et al. · 2015 [cited by applicant]
US 20160115551A1 · Cowens · 2016 [cited by applicant]
US 20170044618A1 · Ellis et al. · 2017 [cited by applicant]
WO WO2015073949A1 · 2015 [cited by applicant]
WO WO2017201164A1 · 2017 [cited by applicant]
WO WO2017201165A1 · 2017 [cited by applicant]
Wolfgang Enard, et al. “Intra- and Interspecific Variation in Primate Gene Expression Patterns” Science. Apr. 12, 2002; 296(5566):340-3. (Year: 2002). [cited by examiner]
Extended European Search Report issued by the European Patent Office for Application No. 19755024.7, dated Oct. 27, 2021, 9 pages. [cited by applicant]
Mcconkey et al., Genetic subtypes of invasive bladder cancer, Curr Opin Urol 25(5):449-458 (2015). [cited by applicant]
Bibikova et al., “Quantitative gene expression profiling in formalin-fixed, paraffin-embedded tissues using universal bead arrays,” Am J. Pathol 165:1799-1807 (2004). [cited by applicant]
Bindea et al., “Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer,” Immunity 39(4); 782-795 (2013). [cited by applicant]
Bolstad et al., “A comparison of normalization methods for high density oligonucleotide array data based on variance and bias,” Bioinformatics Bioinformatics 19(2):185-193 (2003). [cited by applicant]
Brenner et al., “Gene expression analysis by massively parallel signature sequencing (MPSS) on microbead arrays,” Nat. Biotech. 18:630-634 (2000). [cited by applicant]
Broomhead DS, Jones R, King GP., “Comment on Singular-value decomposition and embedding dimension,” Phys Rev A Gen Phys. Jun. 15;37(12):5004-5005 (1988). [cited by applicant]
Carter, S. L. et al., “Absolute quantification of somatic DNA alterations in human cancer,” Nat. Biotechnol. 30:413-421 (2012). [cited by applicant]
Charoentong, P., et al., “Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade,” Cell Reports 18(1): 248-262 (2017). [cited by applicant]
Clark et al., “Suppression of nonspecific binding of avidin-biotin complex (ABC) to proteins electroblotted to nitrocellulose paper,” J Histochem Cytochem 34:1509-1512 (1986). [cited by applicant]
Cronin et al., “Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay,” Am. J Pathol. 164(1):35-42 (2004). [cited by applicant]
Dabney AR ClaNC: Point-and-click software for classifying microarrays to nearest centroids. Bioinformatics. 2006;22: 122-123. [cited by applicant]
Dabney, “Classification of microarrays to nearest centroids,” Bioinformatics 21(22):4148-4154 (2005). [cited by applicant]
Faruki et al., “Lung Adenocarcinoma and Squamous Cell Carcinoma Gene Expression Subtypes Demonstrate Significant Differences in Tumor Immune Landscape,” Journal of Thoracic Oncology 12(6):943-953 (2017). [cited by applicant]
Fishel and Kaufman et al., “Meta-analysis of gene expression data: a predictor-based approach,” Bioinformatics 23(13): 1599-1606 (2007). [cited by applicant]
Fox et al., “Formaldehyde Fixation,” J Histochem Cytochem 33:845-853 (1985). [cited by applicant]
Friedman et al., “Regularization Paths for Generalized Linear Models via Coordinate Descent,” Journal of statistical software 33(1): 1-22 (2010). [cited by applicant]
Geiss et al., “Direct multiplexed measurement of gene expression with color-coded probe pairs,” Nat. Biotechnol. 26:317-325 (2008). [cited by applicant]
Glaser et al. “APOBEC-mediated mutagenesis in urothelial carcinoma is associated with improved survival, mutations in DNA damage response genes, and immune response,” Oncotarget 9(4):4537-4548 (2017). [cited by applicant]
Guatelli et al., “Isothermal, in vitro amplification of nucleic acids by a multienzyme reaction modeled after retroviral replication,” Proc. Natl. Acad. Sci. USA 87:1874-1878 (1990). [cited by applicant]
Hoadley et al, “Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer,” Cell 173(2):291-304 (2018). [cited by applicant]
International Search Report and Written Opinion issued by the International Searching Authority for Application No. PCT/US2019/017799, dated Jul. 3, 2019, 12 pages. [cited by applicant]
Irizarry et al., “Exploration, normalization, and summaries of high density oligonucleotide array probe level data,” Biostatistics April 4(2): 249-64 (2003). [cited by applicant]
Krupenko et al. “Chapter 11: ALDH1L1 and ALDH1L2 Folate Regulatory Enzymes in Cancer,” AEMB:Alcohol and Cancer 103:127-143 (2018). [cited by applicant]
Kwoh et al., “Transcription-based amplification system and detection of amplified human immunodeficiency virus type 1 with a bead-based sandwich hybridization format,” Proc. Natl. Acad. Sci. USA 86:1173-77 (1989). [cited by applicant]
Landergren et al., “A Ligase-Mediated Gene Detection Technique,” Science 241:1077-1080 (1988). [cited by applicant]
Martin, M., et al., “PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer,” Breast Cancer Res Treat 138:457-466 (2013). [cited by applicant]
Mayhew et al. “Abstract 4538: Bladder cancer gene expression subtypes (60 gene signature) to define prognosis, differential immune response, and biomarker associations,” Journal of Clinical Oncology 36(15):4538-4838 (20… [cited by applicant]
McGhee and von Hippel, “Formaldehyde as a probe of DNA structure. II. Reaction with endocyclic amino groups of DNA bases,” Biochemistry 14:1281-1296 (1975). [cited by applicant]
Mullins et al., “Agreement in breast cancer classification between microarray and quantitative reverse transcription PCR from fresh-frozen and formalin-fixed, paraffin-embedded tissues,” Clin Chem. 53(7):1273-1279 (2007… [cited by applicant]
Paolillo et al., “Small molecule integrin antagonists in cancer therapy,” Mini Rev Med Chem 12:1439-1446 (2009). [cited by applicant]
Parzen, “On Estimation of a Probability Density Function and Mode,” Stanford University, 1065-1076 (1962). [cited by applicant]
Quinlan, “Induction of Decision Trees,” Machine Learning 1(1):81-106 (1986). [cited by applicant]
Robertson, AG, et al., “Comprehensive molecular characterization of muscle invasive bladder cancer,” Cell, 171(3): 540-556 (2017). [cited by applicant]
Robin et al., “pROC: an open source package for R and S+ to analyze and compare ROC curves,” BMC bioinformatic 12:77 (2011), 8 pages. [cited by applicant]
Rouskin et al., “Genome-wide probing of RNA structure reveals active unfolding of mRNA structures in vivo,” Nature 505, pp. 701-705 (2014). [cited by applicant]
Seiler, R., et al., “Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy,” Eur Urol 72(4):544-554 (2017). [cited by applicant]
Sjodahl, G., et al., “A Molecular Taxonomy for Urothelial Carcinoma,” Clin Cancer Res, 18(12):3377-3386 (2012). [cited by applicant]
Smyth, G. K., Limma: linear models for microarray data. In: Bioinformatics and Computational Biology Solutions using Rand Bioconductor, R. Gentleman, V. Carey, S. Dudoit, R.Irizarry, W. Huber (eds.), Springer, New York,… [cited by applicant]
Smyth, G. K., “Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments,” Stat. Appl. Genet. Mol. Biol. 3: Article 3 (2004), 28 pages. [cited by applicant]
Suykens JAK, Vandewalle J., “Least Squares Support Vector Machine Classifiers,” Neural Processing Letters 9(3): 293-300 (1999). [cited by applicant]
Szumilas, “Explaining odds ratios,” J. Can. Acad. Child Adolesc. Psychiatry 19(3): 227-229 (2010). [cited by applicant]
The Cancer Genome Atlas Research Network, “Comprehensive molecular characterization of urothelial bladder carcinoma,” Nature, 507(492): 315-22 (2014). [cited by applicant]
Thorsson, V. et al., “The immune landscape of cancer,” Immunity, 48(4), pp. 812-830 (2018). [cited by applicant]
Tibshirani et al., “Diagnosis of multiple cancer types by shrunken centroids of gene expression,” Proc. Natl. Acad. Sci. USA 99(10):6576-6572 (2002). [cited by applicant]
Trapnell et al., “TopHat: discovering splice junctions with RNA-Seq.,” Bioinformatics 25(9):1105-1111 (2009). [cited by applicant]
Velculescu et al., “Serial analysis of gene expression,” Science 270(5235):484-487 (1995). [cited by applicant]
Wold, et al., “Genome expression and mRNA maturation at late stages of productive adenovirus type 2 infection,” J Virol. Nov. 1976;20(2):465-77. [cited by applicant]
Wu and Wallace, “The ligation amplification reaction (LAR)—amplification of specific DNA sequences using sequential rounds of template dependent ligation.,” Genomics, 4(4):560-569 (1989). [cited by applicant]
Cited By (1)
US 12,497,660